Qiagen

Company Overview

QIAGEN develops, manufactures, and markets sample and assay technologies, molecular testing systems, and bioinformatics software that support applications across molecular diagnostics, applied testing, academic research, and pharmaceutical research. Headquartered in Venlo, the Netherlands, with operational headquarters in Hilden, Germany, it serves more than 500,000 customers worldwide through solutions that span sample preparation, PCR and digital PCR, next-generation sequencing (NGS), and data analysis.

In cancer profiling, QIAGEN provides integrated workflows that combine NGS panels, PCR/digital PCR assays, liquid biopsy solutions, and oncology-focused bioinformatics. These instruments, reagents, kits, and consumables are included in the report scope as NGS instruments, reagents, and kits for genomic and transcriptomic profiling, along with digital PCR platforms, oncology assay kits, and bioinformatics tools. QIAGEN maintains manufacturing, R&D, and commercial operations across North America, Europe, and Asia-Pacific, selling products through direct sales organizations and distributor networks.

Financial Highlights (FY 2025)

Company's Business Segments

• Consumables and related revenues : Consumables kits, bioinformatics solutions, royalties, co-development milestone payments and services
• Instruments : It includes PCR instruments, sample technology instruments which includes nucleic acid purification, quality control and accessories.